ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2647

Flares and Long-term Remission in Large-vessel Giant Cell Arteritis in Northern Italy: Characteristics and Predictors in a Long-term Follow-up Study

Carlo Salvarani1, Luigi Boiardi 2, Alberto Cavazza 3, Massimiliano Casali 4, Lucia Spaggiari 5, Luca Cimino 6, Raffaella Aldigeri 7, Francesco Muratore 8, Giovanna Restuccia 8, Nicolò Pipitone 5 and Pierluigi Macchioni 5, 1Azienda USL-IRCCS di Reggio Emilia, REGGIO EMILIA, Emilia-Romagna, Italy, 2Division of Rheumatology, Azienda Unita' Sanitaria Locale IRCCS di Reggio Emilia, Reggio Emilia, Italy, 3Pathology Unit, Azienda Unita' Sanitaria Locale IRCCS di Reggio Emilia, Reggio Emilia, Italy, 4Azienda USL-IRCCS di Reggio Emilia, REGGIO EMILIA, Italy, 5Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, 6Ophthalmology Unit, Azienda Unita' Sanitaria Locale IRCCS di Reggio Emilia, Reggio Emilia, Italy, 7Università degli Studi di Parma, Parma, 8Division of Rheumatology, Azienda Unita’ Sanitaria Locale IRCCS di Reggio Emilia, Reggio Emilia, Italy

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: giant cell arteritis and large vessel vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Giant Cell Arteritis

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: To evaluate the frequency, timing, and characteristics of flares and to evaluate the frequency of long-term remission after glucocorticoids (GCs) suspension in an Italian cohort of patients with large-vessel (LV) giant cell arteritis (GCA) and to identify factors that may predict the occurrence of flares and long-term remission.

Methods: We evaluated 75 patients with LV GCA diagnosed and followed up at the Rheumatology Unit of Reggio Emilia Hospital (Italy) for whom information was available from the time of diagnosis until at least 2 years of follow-up. In all patients the diagnosis of LV GCA was confirmed by imaging. Flares were defined as reappearance of signs/symptoms or worsening in vascular imaging requiring treatment adjustment. Long-term remission was defined as complete clinical remission without elevation of inflammatory markers for at least one year after the GC withdrawal.

Results: 34 patients (45.3%) experienced one or more flares. Twenty (38.5%) of the 52 total flares were experienced during the first year after diagnosis. The majority of relapses occurred with doses of prednisone < 10 mg/day (80.7%), while only 3.8% for doses > 25 mg/day. Polymyalgia rheumatica (PMR) (34.6%) and worsening of LV imaging (34.6%) were the most frequently observed flaring manifestations. Cumulative prednisone dose during the first year and total cumulative prednisone dose were significantly higher in flaring patients compared to those without flares (p = 0.006 and p = 0.0001, respectively). The total duration of prednisone treatment was longer in flaring patients (p = 0.0001).
Patients with disease flares had at diagnosis more frequently fever > 38°C (p = 0.04) and less frequently jaw claudication (p = 0.02) compared to those without flares. In the multivariate model fever > 38 °C (HR 2.94, 95%CI:1.25-6.91, p = 0.01), PMR (HR 3.59, 95%CI: 1.61-8.03, p= 0.002), visual manifestations (HR 3.24, 95%CI: 1.09-9.67, p = 0.035) were significantly associated with an increased risk of flares, while jaw claudication (HR 0.11, 95%CI: 0.02-0.48, p = 0.004) with a reduced risk.
33 patients (44%) experienced long-term remission. PMR and disease flares were less frequently observed in patients with long-term remission compared to those without (p = 0.002 and p < 0.0001, respectively). The initial prednisone dosage was higher in patients with long-term remission (p = 0.03), while the total cumulative prednisone dose and the duration of prednisone treatment were significantly lower (p = 0.02 and p = 0.003, respectively). In the multivariate model the duration of prednisone treatment was significantly negatively associated with long-term remission (HR 0.97, 95%CI: 0.96-0.98, p < 0.0001).

Conclusion: In our cohort of patients with LV GCA a flaring course and long-term remission were observed in around half of the patients.


Disclosure: C. Salvarani, None; L. Boiardi, None; A. Cavazza, None; M. Casali, None; L. Spaggiari, None; L. Cimino, None; R. Aldigeri, None; F. Muratore, None; G. Restuccia, None; N. Pipitone, None; P. Macchioni, None.

To cite this abstract in AMA style:

Salvarani C, Boiardi L, Cavazza A, Casali M, Spaggiari L, Cimino L, Aldigeri R, Muratore F, Restuccia G, Pipitone N, Macchioni P. Flares and Long-term Remission in Large-vessel Giant Cell Arteritis in Northern Italy: Characteristics and Predictors in a Long-term Follow-up Study [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/flares-and-long-term-remission-in-large-vessel-giant-cell-arteritis-in-northern-italy-characteristics-and-predictors-in-a-long-term-follow-up-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/flares-and-long-term-remission-in-large-vessel-giant-cell-arteritis-in-northern-italy-characteristics-and-predictors-in-a-long-term-follow-up-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology